Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007131.pdf
0001415889-22-007131.rtf
0001415889-22-007131.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007134.pdf
0001415889-22-007134.rtf
0001415889-22-007134.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-074754.pdf
0001104659-22-074754.rtf
0001104659-22-074754.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001415889-22-006973.pdf
0001415889-22-006973.rtf
0001415889-22-006973.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-006974.pdf
0001415889-22-006974.rtf
0001415889-22-006974.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-073923.pdf
0001104659-22-073923.rtf
0001104659-22-073923.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-069501.pdf
0001104659-22-069501.rtf
0001104659-22-069501.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-006308.pdf
0001415889-22-006308.rtf
0001415889-22-006308.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-006307.pdf
0001415889-22-006307.rtf
0001415889-22-006307.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-005656.pdf
0001415889-22-005656.rtf
0001415889-22-005656.xls